40results about How to "Reduce the frequency of dosing" patented technology

The invention provides an intelligent medicine box system, which includes an intelligent medicine box and an external terminal; the intelligent medicine box includes an upper cover, a shell, a medicine cover layer, a medicine placement layer, and a circuit board; the intelligent medicine box also includes a control module , a power supply module, a display module, a detection module and a communication module; the invention also provides a control method for the intelligent medicine box system. The beneficial effects of implementing the present invention are: 1, the medicine box can be opened in multiple layers, which facilitates the replacement between the parts; Leakage occurs during the cleaning process with water and affects other electronic components of the medicine box; 3. The design of the first terminal and the second terminal enables the guardian and the person taking the medicine to know the situation of taking the medicine in time; 4. The designated indicator light flashes and monitors taking the medicine Whether the user opens the corresponding small cover, which reduces the possibility of the drug user taking the wrong drug.

The invention discloses a method for preparing high-quality LMW (low molecular weight) heparins. Based on an improved beta-elimination and degradation method, through innovatively adding a heavy salinization method, a polyphosphazene alkaline hydrolysis method and a saponification method and the like, the key problems that in feed liquid, more macromolecular heparins exist, and micromolecular heparins are accumulated, and the like are solved, thereby preparing super small molecular fragments. The average molecular weight of ultralow molecular heparin sodium prepared by using the method above is 2000-3000, the molecular weight distribution of the heparin sodium is as follows: the proportion of the molecular weight less than 1600 is less than or equal to 40.0%; and the proportion of the molecular weight greater than 4500 is less than or equal to 11.0%; the rate of the resistant FXa / FIIa is greater than 30, wherein the valence of the resistant FXa is 145-180 IU / mg, and the valence of the resistant FIIa is less than 5.0 IU / mg. Compared with low molecular heparin sodium and ultralow molecular heparin sodium, the high-quality LMW heparin sodium has an extremely good antithrombotic activity, a smaller bleeding risk and a lower influence on platelets, therefore, the high-quality LMW heparin sodium is expected to be a new-generation heparin antithrombotic medicament.

The invention discloses a medicine composition for treating skin diseases. The medicine composition contains the following raw material medicines in parts by weight: 1 part of doramectin and 1-2 parts of terbinafine. The invention further provides a preparation method for the medicine composition and an application of the medicine composition in preparation for a medicine for treating skin diseases. Pharmacological experiments indicate that the medicine composition disclosed by the invention is safe and free from toxic and side effects, fast to become effective and high in effective rate, low in medication dose and low in administration frequency, as well as wide in selective dosage forms, simple in administration mode, and suitable for large-scale clinic popularization and application.

The invention provides a novel compound capable of effectively inhibiting ATX. The compound is a compound represented by formula I, or a tautomer, a stereoisomer, a hydrate, a solvate, a salt or a prodrug of the compound represented by formula I. In the formula I, R1 and R2 are independently selected from-H or-CH3, respectively, with the proviso that R1 and R2 are not-H or-CH3 at the same time.

The invention discloses AST (astaxanthin)-supported phospholipid nanoparticles and a preparation method thereof. The phospholipid nanoparticles are obtained by mixing an organic phase in which a highmolecular polymer and astaxanthin are dissolved and a water phase in which phospholipid are dissolved by emulsion solvent volatilization, wherein the high molecular polymer is single MPEG-PLA (methoxypoly(ethylene glycol)-poly(lactide) copolymer), and phospholipid is DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine). Astaxanthin is subjected to entrapment modification of the phospholipid nanoparticles, the dissolution characteristic and size of astaxanthin are changed, and water solubility of lipid-soluble drug astaxanthin is greatly improved; meanwhile, astaxanthin is endowed with slow release characteristic by the phospholipid nanoparticles, that is, the drug is continuously and slowly released after entering cells of pathological changes, so that the administration frequency can be reduced, and the treatment effect can be enhanced.

The invention discloses an automatic medicine dispensing system. The automatic medicine dispensing system comprises an automatic medicine dispensing controller, a medicine discharging control machine,a medicine feeding device, a storage unit and an indicating unit; the medicine discharging control machine is connected with the automatic medicine dispensing controller, and a plurality of medicineslots for storing medicines are arranged in the medicine discharging control machine; the medicine feeding device is connected with the automatic medicine dispensing controller and used for placing the medicines to the corresponding medicine slots; the medicine dispensing frequency of the corresponding stored medicines in the multiple medicine slots and the medicine feeding time of the corresponding stored medicines are stored in the storage unit; and the indicating unit is connected with the automatic medicine dispensing controller and used for indicating medicine storing states of the multiple medicine slots. Time of taking out each unit of the medicines is confirmed by the automatic medicine dispensing controller according to the medicine dispensing frequency of each of the medicines, the time of taking out each unit of the medicines is compared with medicine feeding time of each of the medicines, the amount of the limit surplus medicines in the medicine slots is confirmed accordingto the match degree of the time of taking out each unit of the medicines and the medicine feeding time of each of the medicines, the indicating unit is controlled to operate indicating when the amount of medicines is less than the amount of the limit surplus medicines, and medicine feeding instructions are sent to the medicine feeding device.

The invention discloses a nasal cavity nano autophagy inducer for preventing and treating early neurodegenerative diseases and a preparation method thereof. The inducer comprises a hydrophobic small molecule having an autophagy induction effect and an amphiphilic surfactant; firstly, a good solvent solution is arranged, a self-carrying carrier-free nanoparticle suspension emulsion is prepared by areprecipitation method, and is freeze-dried to prepare lyophilized powder; before use, the lyophilized powder is resuspended in isotonic physiological saline to obtain the nasal cavity nano autophagyinducer. The nasal cavity nano autophagy inducer can be absorbed through mucosa of an olfactory region by nasal cavity administration, firstly reach and be enriched in olfactory-related regions of abrain, have a special relief effect for common symptom dysosmia of the early neurodegenerative diseases, have a significant clearing effect on abnormal protein aggregation in the olfactory regions andother lesion regions, and be of importance for preventing the further deterioration of the early neurodegenerative diseases such as AD, PD and the like. The inducer has no carrier, no biodegradationproblem and accumulation toxicity, and the drug loading rate is as high as 25% or more.

The invention discloses a phospholipid nanoparticle loaded with astaxanthin (AST) and a preparation method thereof. The phospholipid nanoparticle is obtained by mixing an organic phase in which a polymer and astaxanthin are dissolved with an aqueous phase in which a phospholipid is dissolved. Obtained by emulsified solvent evaporation method, in which the polymer is monomethoxypolyethylene glycol-polylactic acid (MPEG-PLA), and the phospholipid is dimyristoylphosphatidylcholine (DMPC). The invention changes the solubility and size of astaxanthin by carrying out phospholipid nanoparticles loading modification on astaxanthin, greatly improves the water solubility of fat-soluble drug astaxanthin, and at the same time, the phospholipid nanoparticles endows astaxanthin with slow-release characteristics , that is, the drug is released slowly after entering the cells of the lesion, which can reduce the frequency of administration and enhance the therapeutic effect.

The invention discloses a diphtheria toxin loaded microneedle used for scar repair, and a preparation method of the diphtheria toxin loaded microneedle. The microneedle is a hydrogel microneedle which loads diphtheria toxins. The microneedle is prepared by curing a hydrogel precursor solution mixed with the diphtheria toxin in a microneedle template. The hydrogel precursor is selected from one or more of chitosan, gelatin, silk fibroin, hyaluronic acid, sodium alginate, polyvinyl alcohol, polyethylene glycol, carboxymethyl cellulose, methacrylate gelatin, polyethylene glycol diacrylate, polylactic acid, polylactic acid-glycolic acid copolymers, polyvinylpyrrolidone and polydopamine. The diphtheria toxin loaded microneedle has the advantages of being high in permeability, simple in operation and the like, and can reduce administration frequency.

An in-situ hydrogel composition using nanomicelle as a crosslinking agent and its application. The invention discloses an in-situ hydrogel composition and application suitable for local co-delivery of macromolecular drugs and / or small molecular drugs. Using functionalized micelles as insoluble small molecule solubilization carriers and cross-linking hydrophilic polymer hydrogel framework materials to construct network-like three-dimensional hydrogel structures to achieve locally controlled release of small molecule drugs and biomacromolecular drugs . The in-situ hydrogel composition of the present invention realizes local controllable delivery of small-molecule drugs through the terminal-functionalized micelles as solubilization carriers for insoluble drugs, and the functionalized terminal groups are used as cross-linking agents for hydrogels, Cross-linking with chain-like hydrophilic polymer materials modified by side chain functionalization to construct a hydrophilic network three-dimensional gel structure. Local administration of small molecules for photothermal therapy can effectively improve the photothermal efficiency of photothermal agents and the photothermal stability after repeated irradiation, and can be used in adjuvant therapy after tumor surgery.

The invention discloses mucous membrane adhering microsphere carrying mucous membrane penetrating nanoparticles and a preparation method. The preparation method includes: adopting an emulsifying method to prepare a medicine-containing nanoparticle emulsion as a core; adopting an electrostatic spraying method to prepare the nanoparticle emulsion into microspheres to obtain the mucous membrane adhering microsphere carrying mucous membrane penetrating nanoparticles. Mucous membrane adhering medicine and mucous membrane penetrating medicine are combined to prepare microspheres effectively adheredon the surface of a mucous membrane, and the mucous membrane penetrating nanoparticles are slowly released in the process of degrading the microspheres, so that the problem that the mucous membrane adhering medicine is low in administration efficiency and the problem that the mucous membrane penetrating medicine is difficult to break away from chime are solved, and administration efficiency is improved.

The invention provides a pyrrolopyrimidine derivative and application thereof, and particularly provides a novel compound capable of effectively inhibiting ATX. The novel compound is a compound as shown in a formula (I) which is described in the specification, or a tautomer, a stereoisomer, a hydrate, a solvate, salt or a prodrug of the compound as shown in the formula (I).

The invention relates to the technical field of drag reducers, in particular to a high-efficiency drag reducer and its application method. A high-efficiency drag reducer, including A component and B component; the preparation raw material of the A component includes polyquaternium-11; the B component is an α-olefin copolymer; the B component The raw materials for preparation include long-chain alkyl methacrylate, acrylic acid, initiator, and emulsifier; the mass ratio of the A component to the B component is 1: (0.8-1.2). The high-efficiency drag reducer of the invention has strong shear resistance, which helps to reduce the turbulent flow resistance of oil products, increase the flow velocity, and improve the pipeline delivery volume.

A pyrimidine derivative and its preparation method and use. The invention discloses a compound represented by formula I or its crystal form and salt: wherein, R1 is selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, amino or substituted amino, and R2-R4 are respectively or At the same time, it is selected from hydrogen, alkali metals, and C1-C6 alkyl groups. The SNNP of compound 1 of the present invention is used as a drug carrier, which significantly improves the therapeutic effect of monomeric nucleoside drugs and / or oligonucleotide drugs, has a good sustained-release effect, enhances the therapeutic effect of drugs, and reduces the dosage of drugs and the frequency of administration, improve the bioavailability of the drug, reduce the toxic and side effects of the drug, and have good clinical application value; at the same time, the preparation method of the present invention has high yield, high purity, low energy consumption, few steps, and easy operation , low cost, environmental protection, safety and other advantages, very suitable for industrial applications.

The present invention proposes a new compound that effectively inhibits ATX, which is a compound represented by formula I, or a tautomer, stereoisomer, hydrate, solvate, salt or prodrug of the compound represented by formula I: where: R 1 and R 2 independently selected from -H or -CH 3 , provided that R 1 and R 2 Not both ‑H or not both ‑CH 3 .

The invention discloses a nanometer chitosan artemisinin compound that comprises, based on weight percentage, the following components: 40%-80% artemisinin or artemisinin derivatives; 1%-5% of polyvinyl pyrrolidone, and 15%-50% of nanometer chitosan. The nanometer chitosan artemisinin compound prepared by the invention is water-soluble artemisinin with good solubility, and can be easily absorbed by human body with no toxic and side effect; the nanostructured of which has slow release effect; the medicament half life is substantially improved; the feeding frequency is reduced; the patient compliance is increased; the drug resistance is prevented from forming; the biology utilization rate of artemisinin and derivatives are raised; and the treatment effect is increased.

The invention discloses a self-carrying carrier-free nasal cavity nano-preparation brain-targeted delivery system modified by chitosan oligosaccharides and a preparation method thereof. Including hydrophobic small molecule drugs with neuroprotective effects, polyethylene glycol derivatives, and chitosan oligosaccharides. The present invention also provides a preparation method for the brain-targeted delivery system of the nasal cavity nano-preparation. The first step is to prepare the freeze-dried powder of nanoparticles, and the second step is to stir the freeze-dried powder and chitosan oligosaccharide in isotonic saline before use to form a nasal cavity preparation with good membrane permeability. The preparation method of the system of the present invention is simple, can improve the hydrophobicity of small molecule drugs, reduce toxicity, and enhance neuroprotective effect; there is no carrier, no biodegradation problem and accumulation toxicity, the drug loading rate is as high as 25%, and the membrane is permeable after being modified by chitosan oligosaccharides Absorption is good, and the drug is delivered into the brain with high targeting. The administration method of the dosage form is nasal drop, spray, etc., and the operation is simple, which is convenient for patients who take medicine for a long time, and has a good application prospect in the treatment of nervous system diseases.